Mike Willis was intrigued when he heard about a study aimed at determining the effectiveness of third-dose COVID-19 vaccine boosters for organ transplant recipients. UHN said the study is the first randomized placebo-controlled trial of COVID-19 boosters in transplant patients. In healthy people, antibody levels after two doses typically reach 1,000 to 10,000 units per millilitre, Kumar said, and some of the transplant study participants showed similar numbers. A national study by the same UHN team will look at blood samples of transplant patients who received either Pfizer or Moderna as their third dose. Like many transplant patients, Willis relies on those around him to get vaccinated themselves to lessen the chance he'll be exposed to the virus.

Source: CBC News August 11, 2021 23:37 UTC